<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giannos, A.</style></author><author><style face="normal" font="default" size="100%">Filipits, M.</style></author><author><style face="normal" font="default" size="100%">Zagouri, F.</style></author><author><style face="normal" font="default" size="100%">Brandstetter, A.</style></author><author><style face="normal" font="default" size="100%">Tsigginou, A.</style></author><author><style face="normal" font="default" size="100%">Sotiropoulou, M.</style></author><author><style face="normal" font="default" size="100%">Papaspyrou, I.</style></author><author><style face="normal" font="default" size="100%">Sergentanis, T.N.</style></author><author><style face="normal" font="default" size="100%">Psaltopoulou, T.</style></author><author><style face="normal" font="default" size="100%">Rodolakis, A.</style></author><author><style face="normal" font="default" size="100%">Antsaklis, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Dimitrakakis, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression of ARs in triple negative breast cancer tumors: A potential prognostic factor?</style></title><secondary-title><style face="normal" font="default" size="100%">OncoTargets and Therapy</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">AR</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Triple negative breast cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938150602&amp;doi=10.2147%2fOTT.S78254&amp;partnerID=40&amp;md5=c7483f937190a772d9d4fc1b800891bf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">1843 - 1847</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background/aim: In light of the controversial published literature, this study aims to examine the potential prognostic role of AR immunohistochemical expression in triple negative breast cancer (TNBC). Patients and methods: Ninety patients with TNBC were included in this study; the associations between AR expression (Allred score), clinicopathological variables (stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression), and overall survival were evaluated. Results: AR expression was not associated with stage, grade, histological subtype, tumor size, nodal status, age at diagnosis, Ki67 expression, and p53 expression. AR immunopositivity was not associated with overall survival either at the univariate or at the multivariate Cox regression analysis (multivariate hazard ratio =0.66, 95% confidence interval: 0.26–1.70, P=0.393). Conclusion: AR expression does not seem to play a prognostic role in TNBC. © 2015 Giannos et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2Export Date: 21 February 2017</style></notes></record></records></xml>